Relapsing Multiple Sclerosis (RMS) Overview

Save information for later
Sign Up

Learn About Relapsing Multiple Sclerosis (RMS)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Relapsing Multiple Sclerosis (RMS) Local Doctors?
Daniel Ontaneda
Elite in Relapsing Multiple Sclerosis (RMS)
Elite in Relapsing Multiple Sclerosis (RMS)

Cleveland Clinic Main Campus

1950 East 89th Street, 
Cleveland, OH 
Languages Spoken:
English, Spanish

Daniel Ontaneda is a Neurologist in Cleveland, Ohio. Dr. Ontaneda is rated as an Elite provider by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and Encephalitis.

Robert Bermel
Elite in Relapsing Multiple Sclerosis (RMS)
Elite in Relapsing Multiple Sclerosis (RMS)

Cleveland Clinic Main Campus

1950 East 89th Street, 
Cleveland, OH 
Experience:
27+ years
Languages Spoken:
English
Offers Telehealth

Robert Bermel is a Neurologist in Cleveland, Ohio. Dr. Bermel has been practicing medicine for over 27 years and is rated as an Elite provider by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Optic Neuritis, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

 
 
 
 
Learn about our expert tiers
Learn More
Scott Newsome
Elite in Relapsing Multiple Sclerosis (RMS)
Elite in Relapsing Multiple Sclerosis (RMS)

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 5, Floor 5, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Neurologist Scott Newsome specializes in the care of patients with neuroimmunological and neuroinflammatory disorders of the central nervous system. He works within the Division of Neuroimmunology and Neurological Infections at The Johns Hopkins Hospital, and has special interest in evaluating and treating patients with multiple sclerosis, transverse myelitis, neuromyelitis optica and stiff person syndrome. After completing fellowship training, Dr. Newsome joined the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers, and he is the director of the Johns Hopkins Neurosciences Consultation and Infusion Center and the Stiff Person Syndrome Center. He is also director of the Johns Hopkins Neuroimmunology and Neurological Infectious Disease Fellowship Program and co-director of the Multiple Sclerosis Experimental Therapeutics Program. Dr. Newsome received his medical degree from the New York College of Osteopathic Medicine, with honors. During his neurology residency, he was awarded the Golden Apple Outstanding Resident Teaching Award, and later was chosen to be chief resident. He subsequently completed a fellowship in neuroimmunology at The Johns Hopkins Hospital with the support of a Sylvia Lawry Physician Fellowship Award from the National Multiple Sclerosis Society. Identifying and testing novel therapies and therapeutic strategies for multiple sclerosis and other neuroimmunological disorders is Dr. Newsome’s main research focus. Other research endeavors include validating the use of new quantitative clinical outcome measures and imaging techniques in multiple sclerosis and identifying risk factors of disease onset and severity, response to treatment and long-term outcomes in neuroimmunological disorders. An adviser for the National Multiple Sclerosis Society and a member of the Miller-Coulson Academy of Clinical Excellence, Dr. Newsome has also served as president of the Consortium of Multiple Sclerosis Centers. Dr. Newsome is rated as an Elite provider by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). His top areas of expertise are Stiff Person Syndrome, Multiple Sclerosis (MS), Transverse Myelitis, and Relapsing Multiple Sclerosis (RMS).

What are the latest Relapsing Multiple Sclerosis (RMS) Clinical Trials?
Match to trials
Find the right clinical trials for you in under a minute
Get started
Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)

Summary: This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, an...